Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Large Volume Increase – Here’s What Happened

Fresenius SE & Co. (OTCMKTS:FSNUY) shares saw an uptick in trading volume on Wednesday. 1,102,757 shares changed hands during mid-day trading, an increase of 559% from the previous session’s volume of 167,361 shares. The stock last traded at $12.45 and had previously closed at $12.08.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on FSNUY shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

Fresenius SE & Co. Stock Performance

The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.41. The firm has a 50 day moving average price of $13.04 and a 200 day moving average price of $12.35. The stock has a market capitalization of $28.09 billion, a PE ratio of 15.78 and a beta of 0.60.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $6.91 billion for the quarter, compared to analysts’ expectations of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. Equities analysts expect that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.